Barinthus Biotherapeutics News and Activities

View the org chart displaying its 14 main executives

Most searched biographies at Barinthus Biotherapeutics

• Bill Enright, Chief Executive Officer and Director
• Joseph Scheeren, Director
• Robin Wright, Chairman of the Board

Popular executive movements at Barinthus Biotherapeutics

• Douglas Swirsky will join the company as Chief Financial Officer and Principal Accounting Officer on May 1, 2026  (posted on April 24 2026).

Create your alert
to follow the executive moves at Barinthus Biotherapeutics.

Barinthus Biotherapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Barinthus Biotherapeutics

• Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Barinthus Biotherapeutics
• Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - Barinthus Biotherapeutics
• Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - Barinthus Biotherapeutics
• Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - Barinthus Biotherapeutics
• Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - Barinthus Biotherapeutics
• View more press releases Close

Social media about Barinthus Biotherapeutics

• Barinthus Biotherapeutics on Wikipedia, Google News & Yahoo Finance
• Barinthus Biotherapeutics on LinkedIn, X (Twitter) & YouTube